Vision loss relentless in advanced AMD patients

Article

Patients who develop advanced age-related macular degeneration (AMD) undergo a precipitous loss of vision, concluded the researchers of this study recently published in the Journal of the American Medical Association Ophthalmology.

Patients who develop advanced age-related macular degeneration (AMD) undergo a precipitous loss of vision, concluded the researchers of this study recently published in the Journal of the American Medical Association Ophthalmology.

Researchers from the National Eye Institute, EMMES Corporation, and the University of Wisconsin followed up on 3,549 patients from the Age-Related Eye Disease Study (AREDS) for an additional 5 years after the initial trial of antioxidant vitamins and minerals was finished. Patients in the initial trial were aged 55 to 80 years and were followed for a median of 6.5 years.

Researchers noted the development of the varying stages of age-related macular degeneration in patients and changes in visual acuity. In addition, they measured the rates of progression to large drusen and advanced AMD with annual fundus photographs assessed centrally. BCVA was also measured annually.

The risk of progression to advanced AMD increased with increasing age (P = 0.01) and severity of drusen. Women and current smokers had an increased risk of neovascular AMD (P = 0.005 and P

Rates of progression to large drusen increased with an increased severity of baseline drusen; a full 70.9% of patients with bilateral medium drusen progressed to large drusen, and 13.8% to advanced AMD in 10 years. Median visual acuity at 10 years in eyes with large baseline drusen who never developed advanced AMD was 20/25. In eyes that did develop advanced AMD, median visual acuity was 20/200.

To read the abstract of this study, click here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.